Circulatory effects of orciprenaline, adrenaline and a new sympathomimetic beta-receptor-stimulating agent, terbutaline, in normal human subjects.
D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D000605:Amino Alcohols / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001993:Bronchodilator Agents / Q000494:pharmacology*; D002302:Cardiac Output / Q000187:drug effects; D002306:Cardiac Volume / Q000187:drug effects; D004837:Epinephrine / Q000494:pharmacology*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D009921:Metaproterenol / Q000494:pharmacology; D008875:Middle Aged; D010627:Phenethylamines / Q000494:pharmacology*; D012118:Resorcinols / Q000494:pharmacology*; D013566:Sympathomimetics / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects*
D000318:Adrenergic beta-Agonists; D000605:Amino Alcohols; D001993:Bronchodilator Agents; D010627:Phenethylamines; D012118:Resorcinols; D013566:Sympathomimetics; D009921:Metaproterenol; D004837:Epinephrine